1. STIVARGA® (regorafenibe). São Paulo: Bayer S.A. VE0118-CCDS10. Bula do paciente. Disponível em: https://consultas.anvisa.gov.br/#/bulario/q/?nomeProduto=Stivarga. Acesso em: 06. abr. 2021.

2. Grothey A, Van Cutsem E, Sobrero A, et al for the CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicenter, randomized, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303-312.• 3. Li J, Qin S, Xu R, et al; on behalf of the CONCUR Investigators. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16(6):619-629

4. Bekaii-Saab, et al. Regorafenib dose optimization study comparing lower dose with standard dose in patients with refractory mCRC – A randomized phase 2 trial. Poster presented at ASCO-GI 2018;Poster 611; ClinicalTrials.gov: NCT02368886